Getting ready for once-weekly basal insulin
Insulin icodec will be the first once-weekly insulin available to patients in Canada. Read about its safety and efficacy based on the latest trials, as well as the pharmacists’ role in helping their diabetes patients better understand their insulin options. This continuing education lesson also explores the key topics to discuss with patients when starting insulin icodec.
This course is accredited by CCCEP for 1.25 CEUs; course number CCCEP is #1329-2024-3805-I-P.
Supported by an unrestricted educational grant from Novo Nordisk Canada
Learning Objectives
Upon successful completion of this continuing education lesson, you will be better able to:
- Explain how once-weekly insulin icodec differs from current once-daily basal insulin therapies.
- Comprehend the evidence for the efficacy and safety of insulin icodec in the management of type 1 and type 2 diabetes.
- Discuss potential barriers to insulin therapy and how once-weekly insulin might help overcome some of these barriers.
- Provide patient counseling tips and instructions on starting and titrating weekly basal insulin.
- Summarize the potential advantages and disadvantages of once-weekly insulin icodec.
Course Author: Nanci Frank
This continuing education is free for members of CanadianHealthcareNetwork.ca. Log in and click here to take the course:
Not a member of CanadianHealthcareNetwork?
Registration is free and easy for qualified healthcare professionals.